By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Wall St. BoltWall St. Bolt
  • Home
  • Stock Market News
  • Economy
  • Latest Stories
  • IPOs – Latest & Upcoming IPO News
Reading: Checkpoint’s Cosibelimab Shows Promising Results for Advanced Skin Cancer
Share
Notification Show More
Latest News
Investors Are Bullish on Nouveau Monde Graphite (NMG)
Stock Market News
SoundThinking (SSTI) Delivers Real-Time Crime Intelligence to Over 2,100 Agencies
Stock Market News
PHX Minerals Could Outperform: Passive Income from Energy Royalties
Stock Market News
Here’s Why Mayville Engineering Is a Strong Buy in 2025
Stock Market News
Atlantic American Corp. (AAME): An Undervalued Stock Poised for a Turnaround
Stock Market News
Aa
Wall St. BoltWall St. Bolt
Aa
  • Home
  • Stock Market News
  • Economy
  • Latest Stories
  • IPOs – Latest & Upcoming IPO News
Have an existing account? Sign In
Follow US
  • Privacy Policy
  • Actionable Feedback Policy
  • Corrections Policy
  • Editorial Guidelines
  • Terms and Conditions Disclosure
© 2023 Wall St Bolt. All Rights Reserved.
Wall St. Bolt > Blog > Stock Market News > Checkpoint’s Cosibelimab Shows Promising Results for Advanced Skin Cancer
Stock Market News

Checkpoint’s Cosibelimab Shows Promising Results for Advanced Skin Cancer

Wall St. Bolt Editorial Team
Last updated: 2024/11/11 at 11:53 AM
Wall St. Bolt Editorial Team 7 months ago
Share
FibroGen (FGEN) Reports Q3 2024 Results: Driving Innovation and Financial Growth
SHARE

Checkpoint Therapeutics, Inc. (CKPT), a clinical-stage immunotherapy and oncology company, revealed promising data for its anti-PD-L1 antibody, cosibelimab, in treating advanced cutaneous squamous cell carcinoma (cSCC) at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona.

Contents
Cosibelimab’s Strong Efficacy in Advanced cSCCCosibelimab’s Safety Profile: A Safer Immunotherapy OptionDual Mechanism of Action: Cosibelimab’s Competitive EdgeCosibelimab Targets Critical Need in Advanced cSCC, Offering Hope for High-Risk PatientsCommercial Outlook: Cosibelimab’s Market Potential

These findings underscore cosibelimab’s potential to redefine cSCC treatment by showcasing enhanced response rates, sustained safety, and robust efficacy.

With a U.S. Food and Drug Administration (FDA) decision on Checkpoint’s Biologics License Application (BLA) anticipated by December 28, 2024, cosibelimab could soon be a powerful new option in the skin cancer treatment landscape.

Checkpoint’s Cosibelimab Shows Promising Results for Advanced Skin Cancer

CHECK THIS OUT: Euroseas (ESEA) Q2 2024 Earnings Surge with 23% Revenue Growth

Cosibelimab’s Strong Efficacy in Advanced cSCC

While many cases are treated with surgery, about 40,000 advance to severe stages, leading to around 15,000 deaths each year.

While surgery manages many cases, around 40,000 progress to advanced stages, causing approximately 15,000 deaths each year.

Complete response rates were also impressive, with 25.8% in locally advanced patients and 12.8% in metastatic patients, indicating significant disease remission for many treated individuals.

These prolonged follow-up results reveal a deepening of response over time, where patient outcomes continued to improve.

Cosibelimab’s median duration of response (DOR) hasn’t been reached yet, suggesting that patients may have long-lasting benefits. This is important for those with life-threatening advanced cSCC.

Cosibelimab’s Safety Profile: A Safer Immunotherapy Option

Cosibelimab has shown a good safety profile, which is important for its use. In a study with 192 advanced cSCC patients, only 3.6% had grade 3 immune-related side effects, and there were no grade 4 or higher cases.

Importantly, there were no grade 3 or higher cases of pneumonitis, colitis, hepatitis, nephritis, or endocrinopathies, often severe in immunotherapy.

Overall, only 6.3% of patients discontinued treatment due to adverse events, mainly related to COVID-19 rather than drug toxicity.

This low adverse event rate makes cosibelimab a safe alternative to other anti-PD-1 therapies, appealing to oncologists seeking safer options for patients.

Dual Mechanism of Action: Cosibelimab’s Competitive Edge

Cosibelimab’s design and unique mechanism make it distinct from other PD-1 and PD-L1 inhibitors.

Cosibelimab binds to PD-L1 and blocks its interaction with PD-1 and B7.1 receptors, enabling T-cells to attack cancer cells. This action removes PD-L1’s suppressive effects on CD8+ T-cells.

Cosibelimab also has an active Fc domain that engages antibody-dependent cellular cytotoxicity (ADCC), allowing immune cells to kill cancer cells directly, potentially increasing its efficacy.

Cosibelimab Targets Critical Need in Advanced cSCC, Offering Hope for High-Risk Patients

Cosibelimab’s development is timely, as advanced cSCC is a major clinical challenge in the U.S., affecting approximately 1.8 million people annually.

While surgery manages many cases, around 40,000 progress to advanced stages, causing approximately 15,000 deaths each year.

Advanced cSCC often appears in critical areas like the head and neck, where tumors invade vital structures, causing severe impairments.

Checkpoint Therapeutics targets this high-need market with cosibelimab, a safer, effective treatment, especially for immune-suppressed patients.

The company’s strategy meets the growing demand for cancer immunotherapies that offer long-term benefits with manageable side effects. This focus is crucial for treating this specific patient group.

Commercial Outlook: Cosibelimab’s Market Potential

Upon approval, cosibelimab would join an evolving field of immunotherapies for skin cancer. Its unique combination of PD-L1 blocking and ADCC capabilities could differentiate it in the market.

Cosibelimab’s commercial potential is strong, given the high cSCC incidence and demand for safer, more effective treatments.

Positioned as a valuable option for oncologists and a key addition to Checkpoint’s portfolio, cosibelimab could become a major player in cancer immunotherapy.

READ ALSO: LexinFintech’s Q2 2024 Revenue Up 19.1% on Strong Credit Services and Cango (CANG) Q3 2024: Strong Profit Growth and Strategic Digital Expansion.

You Might Also Like

Investors Are Bullish on Nouveau Monde Graphite (NMG)

SoundThinking (SSTI) Delivers Real-Time Crime Intelligence to Over 2,100 Agencies

PHX Minerals Could Outperform: Passive Income from Energy Royalties

Here’s Why Mayville Engineering Is a Strong Buy in 2025

TAGGED: Checkpoint Therapeutics Inc. (CKPT)
Wall St. Bolt Editorial Team November 11, 2024
Share this Article
Facebook Twitter Email Print
Posted by Wall St. Bolt Editorial Team
The Wall St. Bolt Editorial Team consists of experienced market analysts and financial writers who are passionate about delivering timely, accurate, and insightful financial news. With backgrounds in economics, journalism, and market research, the team works collectively to provide expert coverage of global markets.
Previous Article Euroseas (ESEA) Q2 2024 Earnings Surge with 23% Revenue Growth
Next Article FDA Approves Iterum (ITRM)’s ORLYNVAH™ for Resistant UTIs
Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Wall-St-Bolt-Transparent

Wall St. Bolt provides real-time, lightning-fast market news and stock updates, keeping you ahead of the curve with the latest insights and trends in the financial world.

Quick Links

  • About Us
  • Contact

Latest News Stories

  • Investors Are Bullish on Nouveau Monde Graphite (NMG)
  • SoundThinking (SSTI) Delivers Real-Time Crime Intelligence to Over 2,100 Agencies
  • PHX Minerals Could Outperform: Passive Income from Energy Royalties
  • Here’s Why Mayville Engineering Is a Strong Buy in 2025
  • Atlantic American Corp. (AAME): An Undervalued Stock Poised for a Turnaround

News Categories

  • Economy
  • Stock Market News
  • IPOs – Latest & Upcoming IPO News

Follow Us on Social Media

© 2024 Wall St. Bolt Media Network. All Rights Reserved.

  • Privacy Policy
  • Actionable Feedback Policy
  • Corrections Policy
  • Editorial Guidelines
  • Terms and Conditions Disclosure
Stay Ahead with the Fastest Stock Market News!

Subscribe for the latest updates on stock market trends, IPOs, and economic news. Get expert analysis and insights delivered straight to your inbox, ensuring you never miss an important market move. Join our community of savvy investors today!

Zero spam, Unsubscribe at any time.

Removed from reading list

Undo
Welcome Back!

Sign in to your account

Lost your password?